Gentler chemo combo shows promise for older leukemia patients
NCT ID NCT07153796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called blinatumomab, given as a shot under the skin, combined with low-intensity chemotherapy for people aged 60 and older (or younger adults who are not healthy enough for strong chemo) with B-cell acute lymphoblastic leukemia. The goal is to see if this combination is safe and works well. Only 3 people are enrolled so far, so results are very early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Blinatumomab (given under the skin) plus low-intensity chemotherapy
What this could lead to
If successful, this could offer a gentler treatment option for older or frail patients with B-cell acute lymphoblastic leukemia, potentially improving outcomes with fewer side effects.
What could go wrong
This is a very early phase 2 trial with only 3 participants, so results may not apply broadly. The combination may still cause serious side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States